Advanced endocrine-driven breast cancer (i.e., cancer which is estrogen/progesterone receptor-positive and HER2-negative) is treated with targeted therapy, consisting of a cyclin-dependent kinase 4/6 inhibitor (CDK 4/6i) and endocrine therapy first, which is a highly effective and well-tolerated treatment. This evidence concerns the gene PGR and cancer.